ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Regulatory news

EU · EU licence (European Commission)

Colchicine (Colchicine Agepha Pharma)

Colchicine AGEPHA Pharma is indicated for secondary prevention of atherothrombotic events in adult patients with coronary disease stable for at least 6 months.

CHMP opinion 21 May 2026 → EU licence 24 Jul 2026 · Agepha Pharma s.r.o.

Research

Rheumatology · Semin Arthritis Rheum · 2026-08-23

In 120 adults with symptomatic knee osteoarthritis (Kellgren-Lawrence grade 2/3), three months of daily colchicine without NSAIDs did not improve knee pain (VAS) versus placebo, nor KOOS function or effusion size; some inflammatory biomarkers, including hsCRP, improved.

RCTn = 120
Samuels et al. CoLchicine for Treatment of OsteoArthritis of the Knee (CLOAK): Clinical and biochemical outcomes from a three-month double-blind, placebo-controlled study

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.